IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (280)	1/9/1997 9:43:00 PM
From: I. Luttichuys	of 1762

Hello Miljenko, No, IDEC also has an asthma drug in the works based on the same technology as the others. Also, IDEC-CE9.1 would make IDEC worth much more than it is on its own merit IMO. Merck calls a rheumatoid arthritis drug without side-effects and effacacy on the order of IDEC's "the Holy Grail" of pharmaceuticals. The market is huge and this would be the ONLY RA medication which actually alters the course of this severely debilitating disease. Currently, patients simply cover pain and often develop side effects of varying severity which can curtail the use of even these. For example: some pain relievers cause ulcers over time. Also, these medications do nothing to prevent the deformity that this disease causes to the hands. I am reminded of the quote from TIME magazine made by the coordinator for IDEC's CE9.1 trial: "The patients were literally dancing in the halls." I fully expect to be dancing in the halls eventually myself. It is estimated that for every 1% market penetration SmithKline makes with IDEC CE9.1, .35 will be added to IDEC's bottom line. If CE9.1 makes it through phase III as it did through phase II and is approved, I expect a lot greater market penetration than 1%. It is possible that the present buying opportunities and volatility in IDEC stock are partly due to investors counting drugs in the pipe-line and not the significance of the approach these drugs employ or the size of the market one will eventually address, but the approach, that is a working immunotherapeutic approach like IDEC's has been a biotech dream for years. In the past immune response against the therapy stopped previous efforts. Now, suddenly, one company has a drug which does not seem to generate a signicant response and the market hasn't seemed to give that company the respect that this event in medicine deserves -- especially a company which holds a patent for the process used to produce these antibodies. I expect IDEC to announce the submission of an NDA soon and the days of $21/share will be gone forever. Drop by anytime to share insight or ask questions! Have a good evening, BENNETT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next